Naturally Acquired Passive Protective Activity against Neisseria meningitidis Group C in the Absence of Serum Bactericidal Activity
Open Access
- 1 October 2004
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (10) , 5903-5909
- https://doi.org/10.1128/iai.72.10.5903-5909.2004
Abstract
The hallmark of immunity to meningococcal disease is a bactericidal titer in serum of ≥1:4 measured with human complement, but this threshold titer may underestimate the extent of protection. We used the infant rat model of meningococcal bacteremia to measure group C passive protective activity in serum samples from 91 unimmunized adults living in California. A total of 35 sera (38.5%) had passive protective activity. Sera with complement-mediated bactericidal titers of ≥1:4 were 3.4-fold more likely to confer protection (89%) than nonbactericidal sera (26%; P < 0.0001). Thus, bactericidal titers of ≥1:4 are a marker of protection, but this threshold lacks sensitivity for predicting protective activity. We investigated the 73 sera with bactericidal titers of P < 0.001). Thus, protective activity in the absence of bactericidal activity was associated with higher concentrations of anticapsular antibodies, but not all sera with anticapsular antibodies conferred protection. Of 18 nonbactericidal sera with anticapsular antibody concentrations between 0.31 and 0.99 μg/ml, the 11 sera that conferred protection had a higher mean antibody avidity constant (21.9 nM −1 ) than the 7 nonprotective sera (14.6 nM −1 ; P < 0.03). Thus, in sera with titers of <1:4, protective activity is associated with higher-avidity group C anticapsular antibodies, which are present in concentrations insufficient to elicit complement-mediated bacteriolysis in vitro but sufficient to confer protection in an in vivo bacteremia model.Keywords
This publication has 33 references indexed in Scilit:
- Opportunities for Control of Meningococcal Disease in the United StatesAnnual Review of Medicine, 2004
- Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in EnglandClinical and Vaccine Immunology, 2003
- Neonatal meningococcal disease in the United States, 1990 to 1999The Pediatric Infectious Disease Journal, 2003
- Age-Related Disparity in Functional Activities of Human Group C Serum Anticapsular Antibodies Elicited by Meningococcal Polysaccharide VaccineInfection and Immunity, 2003
- Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy AdultsThe Journal of Infectious Diseases, 2002
- Antibody Persistence and Immunological Memory at Age 4 Years after Meningococcal Group C Conjugate Vaccination in Children in the United KingdomThe Journal of Infectious Diseases, 2002
- Opsonophagocytosis of Fluorescent Polystyrene Beads Coupled to Neisseria meningitidis Serogroup A, C, Y, or W135 Polysaccharide Correlates with Serum Bactericidal ActivityClinical and Vaccine Immunology, 2002
- Importance of Complement Source in Measuring Meningococcal Bactericidal TitersClinical and Diagnostic Laboratory Immunology, 2001
- Standardisation and Validation of Serological Assays for the Evaluation of Immune Responses to Neisseria meningitidis Serogroup A and C VaccinesBiologicals, 2000
- Serum bactericidal activity in a secondary school population following an outbreak of meningococcal disease: effects of carriage and secretor statusFEMS Immunology & Medical Microbiology, 1996